Canadian Markets close in 1 hr 21 mins

OncoGenex Pharmaceuticals, Inc. (OGXI)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4529+0.0264 (+6.1899%)
As of 2:39PM EDT. Market open.
People also watch
THLDRPRXOPXAONTXVSTM
Full screen
Previous Close0.4265
Open0.4600
Bid0.4530 x 100
Ask0.4649 x 5300
Day's Range0.4401 - 0.4773
52 Week Range0.3300 - 0.9900
Volume261,541
Avg. Volume328,800
Market Cap13.63M
Beta2.95
PE Ratio (TTM)-0.69
EPS (TTM)-0.66
Earnings DateMar 7, 2017 - Mar 13, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.90
Trade prices are not sourced from all markets
  • Capital Cube9 days ago

    ETFs with exposure to OncoGenex Pharmaceuticals, Inc. : July 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to OncoGenex Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to OGXI-US. Comparing the performance and risk of OncoGenex Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • CNW Grouplast month

    Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC

    Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC

  • PR Newswirelast month

    Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC

    MILL VALLEY, Calif., BOTHELL, Wash. and VANCOUVER, British Columbia, June 13, 2017 /PRNewswire/ -- Achieve Life Sciences, Inc. (Achieve) and OncoGenex Pharmaceuticals, Inc. (OGXI) (OncoGenex) today announced that the Registration Statement on Form S-4 has been declared effective by the Securities and Exchange Commission ("SEC") on June 13, 2017. The special meeting of the OGXI stockholders will be held on August 1, 2017, at 9 a.m. PT at 1191 Second Avenue, Floor 10, Seattle, Washington, 98101. OncoGenex will ask its stockholders to approve the merger with Achieve and the issuance of OncoGenex common stock in the merger pursuant to the merger agreement.